Safety of Hepatitis B Vaccines (Monovalent or as Part of Combination) in Preterm Infants: A Systematic Review
Sicherheit von Hepatitis-B-Impfstoffen (monovalent oder als Teil von Kombinationsimpfstoffen) bei Frühgeborenen: systematische Übersicht
Vaccines · 01.03.2024 · 12 (3) · 261
DOI: 10.3390/vaccines12030261 ↗Auf einen Blick
Die systematische Übersicht fand für Frühgeborene ab 6 Wochen meist nur leichte unerwünschte Ereignisse nach Hepatitis-B-haltigen Impfstoffen. Die Evidenz war sehr niedrig.
Fragestellung
Wie sicher sind Hepatitis-B-Impfstoffe bei Frühgeborenen und wie hoch ist das Risiko unerwünschter Ereignisse nach der Impfung?
Methode
Systematische Übersichtsarbeit; Suche in Ovid MEDLINE, Ovid Embase, Cochrane Central Register of Controlled Trials und CINAHL Plus vom 1. Januar 2002 bis 30. März 2023; narrative Synthese.
Ergebnisse
21 relevante Arbeiten. Die berichteten AEFI-Raten lagen zwischen 0 % und 96 %. Meist waren sie mild, z. B. Reaktionen an der Injektionsstelle, Temperaturinstabilität und selbstlimitierende kardiorespiratorische Ereignisse. 6 Studien berichteten SAE, selten (~1 %).
Einschränkungen
Keine Publikationen zum Zeitpunkt der Geburtsdosis; AEFI-Berichte nur kurzfristig (Stunden bis Tage); große Variabilität zwischen Studien.
Schlussfolgerung der Autor:innen
Hepatitis-B-haltige Impfstoffe erscheinen bei Frühgeborenen ab 6 Wochen relativ gut verträglich. Forschung zur Sicherheit innerhalb von 7 Tagen nach Geburt fehlt, besonders zu Langzeitmorbidität.
Kernaussagen
- AEFI meist leicht und kurzzeitig
- SAE selten, vor allem in Hochrisikogruppen
- Evidenz nach GRADE: sehr niedrig
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Übersichtsarbeit in der Zeitschrift Vaccines, online erschienen am 01.03.2024. Verfasst von Qiao Wen Tee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics, Monash University, 246 Clayton Road, Clayton, Melbourne, VIC 3168, Australia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHMRC Investigator Grant Leadership 1, Fielding Foundation Fellowship 2017, NHMRC (Australia).
Themen: Neonatologie
Abstract (Originalsprache)
Introduction
The World Health Organization (WHO) recommends vaccination against hepatitis B as soon as possible following birth for all infants, regardless of prematurity. Hepatitis B vaccination at birth is clearly justified, represents a crucial step in the global control of perinatally acquired hepatitis B and there are no safety concerns in infants born at term. However, there is limited information on the safety of the hepatitis B vaccine in preterm infants, whose immune responses and morbidity risk differ from those in infants born at term.
Objectives
The objectives of this paper are to systematically review the literature regarding the safety and risk of adverse events following immunisation (AEFIs) associated with the administration of the hepatitis B vaccine (monovalent or as part of a combination vaccine) to preterm infants.
Methods
We performed a search for relevant papers published between 1 January 2002 and 30 March 2023 in the Ovid MEDLINE, Ovid Embase, Cochrane Central Register of Controlled Trials and CINAHL Plus databases. Two authors independently reviewed and analysed each article to include in the systematic review. Narrative synthesis is presented.
Results
Twenty-one relevant papers were identified and included in this systematic review. The vast majority of data pertained to multi-antigen (combination) vaccine preparations and vaccination episodes from 6 weeks of age onwards. We found no publications investigating the timing of the birth dose of the hepatitis B vaccine, and AEFI reporting was exclusively short-term (hours to days following administration). There was substantial variability in the reported rate of AEFIs between studies, ranging from 0% to 96%. Regardless of frequency, AEFIs were mostly minor and included injection site reactions, temperature instability and self-limiting cardiorespiratory events. Six studies reported serious adverse events (SAEs) such as the requirement for escalation of respiratory support. However, these occurred predominantly in high-risk infant populations and were rare (~1%). Using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach, the certainty of evidence was assessed as very low.
Conclusions
Despite substantial variability between the relatively small number of published studies in terms of cohort selection, definitions, vaccine preparations and reporting, hepatitis B-containing vaccines (mostly as combination vaccines) appear to be relatively well tolerated in preterm infants from 6 weeks of age. Research focusing on the safety of hepatitis B vaccine in preterm infants specifically within 7 days of birth is lacking, particularly regarding long-term morbidity risk. Further research in this area is required.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Paediatrics, Monash University, 246 Clayton Road, Clayton, Melbourne, VIC 3168, Australia.
- Infection Control and Epidemiology, Monash Health, Melbourne, VIC 3168, Australia.
- Centre for Health Analytics, Melbourne Children's Campus, Melbourne, VIC 3052, Australia.
- Department of Paediatrics, University of Melbourne, Melbourne, VIC 3052, Australia.
- The Ritchie Centre, Hudson Institute of Medical Research, Melbourne, VIC 3168, Australia.
- Monash Newborn, Monash Children's Hospital, Melbourne, VIC 3168, Australia.
ORCID-Profile: Ramin Odisho, Elisha Purcell, Jim Buttery, Claudia A Nold-Petry, Marcel F Nold, Atul Malhotra
Förderung
- NHMRC Investigator Grant Leadership 1
- Fielding Foundation Fellowship 2017
- NHMRC (Australia)
Zitieren
APA
Tee, Q. W., Odisho, R., Purcell, E., Purcell, R., Buttery, J., Nold-Petry, C. A., Nold, M. F., & Malhotra, A. (2024). Safety of Hepatitis B Vaccines (Monovalent or as Part of Combination) in Preterm Infants: A Systematic Review. Vaccines, 12(3), 261. https://doi.org/10.3390/vaccines12030261
Vancouver
Tee QW, Odisho R, Purcell E, Purcell R, Buttery J, Nold-Petry CA, et al. Safety of Hepatitis B Vaccines (Monovalent or as Part of Combination) in Preterm Infants: A Systematic Review. Vaccines. 2024;12(3):261. doi:10.3390/vaccines12030261
BibTeX
@article{Tee2024,
author = {Tee, Qiao Wen and Odisho, Ramin and Purcell, Elisha and Purcell, Rachael and Buttery, Jim and Nold-Petry, Claudia A and Nold, Marcel F and Malhotra, Atul},
title = {Safety of Hepatitis B Vaccines (Monovalent or as Part of Combination) in Preterm Infants: A Systematic Review},
journal = {Vaccines},
year = {2024},
volume = {12},
number = {3},
pages = {261},
doi = {10.3390/vaccines12030261}
}
EUVIMED